Utility of boron in dermatology

Abstract

Introduction: Boron compounds are being investigated as therapies for dermatologic conditions. Several features of boron chemistry make this element an ideal component in dermatologic treatments. We review the published dermatologically-relevant clinical trials and case studies pertaining to boron compounds.

Methods: PubMed was utilized to query terms boron, chemistry, drug, development, dermatology, atopic dermatitis, psoriasis, onychomycosis, tavaborole, AN 2690, crisaborole, and AN 2728. Clinical trials, case studies, animal studies and in vitro studies. Pertaining to atopic dermatitis, psoriasis and onychomycosis were included.

Results: Crisaborole 2% topical solution reduced atopic dermatitis lesions by ∼60% when compared to pretreatment baseline. Crisaborole maintains its dose-dependent effect in treatment of psoriasis and significantly reduces psoriatic plaques when compared to controls. Adverse effects were mild, frequency of events varied between studies. Crisaborole was well tolerated when applied to sensitive skin. Topical tavaborole significantly reduced or eliminated onychomycosis with minimal side effects compared to placebo. Tavaborole was effective in treating recalcitrant onychomycosis.

Discussion: Boron-based compounds form stable interactions with enzyme targets and are safe medications for the treatment of atopic dermatitis, psoriasis, and onychomycosis. The mild and rare side effects of topical boron-based compounds may make them ideal treatments for individuals with sensitive skin and pediatric populations.

Keywords:

• Atopic dermatitis
• psoriasis
• treatment
• anti-inflammatory
• antifungal

Disclosure statement

Dr. Feldman is a speaker for Janssen and Novartis. Dr. Feldman has received grants from Galderma Laboratories, L.P., Janssen, Abbvie, Amgen, Stiefel/GlaxoSmithKline, Celgene, and Anacor. He is a consultant for Amgen, Baxter, Caremark, Gerson Lehrman Group, Guidepoint Global, Hanall Pharmaceutical Co Ltd, Lilly, Merck, Mylan, Novartis, Pfizer, Qurient, Suncare Research and Xenoport. Dr. Feldman is the founder and holds stock in Causa Research and holds stock and is the majority owner in Medical Quality Enhancement Corporation and the www.DrScore.com doctor rating/patient satisfaction website. He receives Royalties from UpToDate and Xlibris. Dr. Cardwell and Dr. Jackson have no conflicts to disclose. No human subjects were used in this study and the study was deemed exempt from IRB approval by Wake Forest School of Medicine.